Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Michael E. Flaugh
Mark M. Foreman
Michael J. Martinelli
Thomas J. Kress
Marvin R. Leanna
Barry C. Peterson
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/482,811external-prioritypatent/US5204340A/en
Application filed by Michael E. Flaugh, Mark M. Foreman, Michael J. Martinelli, Thomas J. Kress, Marvin R. Leanna, Barry C. Peterson, Eli Lilly And CompanyfiledCriticalMichael E. Flaugh
Publication of CA2037100A1publicationCriticalpatent/CA2037100A1/en
Application grantedgrantedCritical
Publication of CA2037100CpublicationCriticalpatent/CA2037100C/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
The present invention provides 4-amino-6-substituted-hexahydrobenz[cd]indoles which are useful in treating disease states which can be benefited by an alteration of function at 5-HT1A receptors.
CA 20371001990-02-261991-02-266-substituted-hexahydrobenz ¢cd! indoles
Expired - Fee RelatedCA2037100C
(en)